ClinicalTrials.gg
WithdrawnNCT01308047Updated Mar 26, 2014

Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.

A Phase 3 interventional study of Bupivacaine in Fracture of Lower Limb, sponsored by Cristália Produtos Químicos Farmacêuticos Ltda.. Withdrawn at 2 sites in Brazil. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-03-26.

Sponsored by Cristália Produtos Químicos Farmacêuticos Ltda. · Phase 3, Interventional, and Supportive care

Why this study was withdrawn
The Sponsor has no interest in continuing the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to compare the non-inferiority between Heavy Levobupivacaine with Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine During Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.

Read the detailed description

The Heavy Levobupivacaine with Enantiomeric Excess of 50% was developed to be a safe local anesthetic replacing the Heavy Racemic Bupivacaine.

This study will evaluate the non-inferiority regarding efficacy and safety of spinal anesthesia in orthopedic procedures.

02

Conditions studied

  • Fracture of Lower Limb
03

In context

Lead sponsor

Cristália Produtos Químicos Farmacêuticos Ltda. is the lead sponsor of 14 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ASA () I or ASA II
  • Spinal Anaesthesia for lower limb surgery
  • Patient Consent

Exclusion criteria

Exclusion Criteria:

  • relative or absolute for spinal anesthesia
  • history of to the local anesthetics or components
  • opioids for anesthetic adjuvant
  • spinal lesions, peripheral neuropathies or any other neurologic disorders that leads to changes of sensitivity
  • = or > 35
  • lumbar puncture difficulty
  • ventricular extrasystoles
  • dementia, others loss of cognitive ability
  • difficulty in the spine
  • spinal cord surgery
  • anaphylactic reactions or Stevens-johnson Syndrome
  • polytraumatism
  • alcoholism abuse and use of illicit substance
  • Changes in the blood test
  • Others conditions judged by investigator's opinion
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    bupivacaine S75:R25

    3 ml for subarachnoid block

    Drug: Bupivacaine

  • Active comparator
    bupivacaine (S50:R50)

    3 ml subarachnoid block

    Drug: Bupivacaine

Interventions

  • single dose of 15mg by a slow injection rate of 1 ml/s

    Also known as: marcaine

06

What researchers measure

Primary outcomes

  1. Time of latency for sensory block at T10 dermatome.

    Evaluate the sensory block at T10 after the anesthetic injection through sensory stimulation by needle.

    Time frame: +/- 40 min after injection

Secondary outcomes

  1. Sensory block duration

    Verifying the duration of anesthesia from after puncture till the presence of positive sensitivity by needle stimulation region of the foot.

    Time frame: +/- 3 hours

  2. Motor Block Evaluation

    Motor block evaluation by Bromage Scale every five minutes after puncture till 20 minutes.

    Time frame: +/- 30 min

  3. Maximum cranial dispersion verifying the largest metamer achieved.

    Evaluated by needle stimulation every 2 minutes from the removal of post-puncture needle until the maximum extension time.

    Time frame: +/- 45 min

  4. Evaluation of the cardiocirculatory and respiratory parameters

    Systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and oxygen saturation (SpO2) are evaluate during the study to measure the safety of cardiocirculatory and respiratory parameters

    Time frame: +/- 8 hours

  5. Time of regression of motor block by Bromage Scale

    Will be measure the time of recovery of the motor block, the patient have to score note 4 of the Bromage Scale

    Time frame: +/- 9 - 10 hours

  6. The residual analgesic effect

    Will be evaluated the end of the analgesic effect of the anesthetic solution when the patient asks for pain medication.

    Time frame: +/- 9-10 hours

  7. Anesthetic failure

    Evaluation of the anesthetic failure (if occur)

    Time frame: +/- 45 min

  8. Adverse Events

    During the study will be evaluate the presence of adverse event due to the anesthetic.

    Time frame: +/- 8 - 12 hours

07

Study locations

2 sites
  • Hospital Sepaco
    São Paulo, Brazil
  • Irmandade da Santa Casa de Misericórdia de São Paulo
    São Paulo, Brazil
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01308047
Lead sponsor
Cristália Produtos Químicos Farmacêuticos Ltda.
Collaborators
Irmandade da Santa Casa de Misericordia de Sao Paulo, Serviço Social da Indústria do Papel, Papelão e Cortiça do Estado de São Paulo
Responsible party
Sponsor
First posted
Mar 3, 2011
Last update
Mar 26, 2014

Study contacts

Ligia Mathias, PhD
principal investigator · Irmandade da Santa Casa de Misericórdia de São Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion